Translate:
genimaps®
GENIMAPS is a cloud-based, in-silico accelerated drug repositioning and development platform
GENIMAPS overlays available compound databases - as well as entire drug discovery and repositioning pipelines from pharmaceuticals, FDA approved drugs and orphan drugs with profiles of disease relevant genes - to identify new compounds or to repurpose known compounds for the treatment of cardiovascular and cardiometabolic - and cancer.
GENIMAPS utilizes a customized pattern recognition and real-time machine learning alghorithms to perform matches with ever increasingly accuracy and precision
GENIMAPS has the ability to adopt re-classified data from preclinical studies to refine its matching capability. As a cloud based solution, GENIMAPS is dynamic - it automatically and continuously updates, expands and refines its data sources as more data becomes available.
GENIMAPS Advantage
- Dynamic platform which learns as data expands
- Coverage of studies across a variety of species and experimental systems
- Exhaustive data annotation
- Exhaustive data sourcing including transcriptomics, GWAS, CVS and protein interaction
- Highly specific and exhausitive drug alignment algorithm (as opposed to disparate data sources)
- Expert validation of results
- Directly coupled to the GENISYST accelerated preclinical drug testing platform
genisyst®
GENISYST is a patented technology for in vitro and in vivo multiplexed disease modeling
GENISYST can be applied to modulate a combination of coding genes, microRNAs (miRNA) and non-coding RNAs (ncRNA) in specific tissues or cell lineages of the adult, newborn or embryo. GENISYST is also applicable for in vitro 2D and 3D (human tissue organoid) cell culture based drug screens.
Our platform empowers researchers to generate multigenic disease models to interrogate drug action with greater precision and fidelity, or to validate drug specificity and efficacy on a given gene or gene combination.
GENISYST is based on single cell transgenics technology
GENISYST amplifies the throughput of traditional transgenesis and exploits the power of on-demand custom high-content transgenesis. GENISYST has been applied and validated in the brain, kidney, liver, spleen, adipose tissue, skeletal muscle and heart.
GENISYST Advantage
- Fast generation of custom single and multigenic disease models - 2-3 months with GENISYST compared to 2-7 years with other methods
- Can be used as an in-vivo target screening platform
- Can be used to generate genetic mosaic disease models
- 10-fold reduction in preclinical costs - due to reduced animal housing and breeding
- Circumvents the need to age animals in aging-related studies. Models can be generated on-demand directly in aged animals for immediate drug compound testing - currently not possible with any other technology
- GENISYST is applicable in small (mice, rats) and large animals (pig, sheep, NHP) preclinical studies
- When coupled to GENIMAPS, GENISYST can potentially bring a repurposed/orphan drug into Phase II or III Clinical studies in 6-18 months
case study
GENISYST® is based on patented single cell transgenic technology. This single cell transgenesis approach enables testing of up to 50 genes in a target tissue of interest simultaneously - while ensuring that each cell only expresses a single transgene which can then be analysed for its specific drug response.
Conventional transgenics would require a minimum of 50 animals lines to test a library of 50 different genetic disease subtypes. GENISYST can achieve this in 1 mouse. GENISYST facilitates generation of high-content traditional transgenic models or exploits the power of adeno-associated viruses to generate on-demand custom high-content disease or gene target models.
Case study of Diabetic Cardiomyopathy
Aim: Identify genetic drivers of Diabetic Cardiomyopathy
Protocol: Mice were maintained on a Western high fat diet to induce obesity-linked Diabetic Cardiomyopathy. Next, the mice were injected with an adeno-associated virus containing a heart specific GENISYST® construct targeting 20 individual genes or gene combinations identified by GENIMAPS® to promote Diabetic Cardiomyopathy by increasing cardiac lipid accumulation.
Procedure: The GENISYST® modified heart was dissociated to yield individual heart cells. Some of the heart cells contained pathologic high lipid levels while others did not. Using lipid dyes that enter and stain intra-cellular lipids, heart cells were separated by lipid levels using fluorescence-activated cell sorting (FACS). This technique yields defined populations of cells containing varying amounts of lipids based on staining intensity. Selection of cell populations containing negligible amounts of lipids and barcode RT-qPCR, revealed gene targets that prevented lipid accumulation in heart cells. Thus, genes affecting lipid accumulation in the heart was identified.
Perspective: This technique can be applied to other phenotypic readouts including cell size, cell morphology, surface or internal protein expression, apoptosis, proliferation, etc. Essentially any parameter that serves as a phenotypic readout that can be distinguished by staining, size or cell morphology can be applied.
